published meta-analysis   sensitivity analysis   studies

mRNA vaccine in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias adverse eventsdetailed resultsCom-COV, 2021 1.14 [0.78; 1.66] 1.14[0.78; 1.66]Com-COV, 202110%463NAnot evaluable intracranial hemorrhage detailed resultsCom-COV, 2021 1.01 [0.02; 51.28] 1.01[0.02; 51.28]Com-COV, 202110%463NAnot evaluable ischemic strokedetailed resultsCom-COV, 2021 1.01 [0.02; 51.28] 1.01[0.02; 51.28]Com-COV, 202110%463NAnot evaluable Myocardial infarction detailed resultsCom-COV, 2021 1.01 [0.02; 51.28] Reindl-Schwaighofer, 2021 2.03 [0.07; 61.21] 1.51[0.11; 19.72]Com-COV, 2021, Reindl-Schwaighofer, 202120%664NAnot evaluable pulmonary embolismdetailed resultsCom-COV, 2021 1.01 [0.02; 51.28] 1.01[0.02; 51.28]Com-COV, 202110%463NAnot evaluable serious adverse events (SAE), anydetailed resultsReindl-Schwaighofer, 2021 1.53 [0.25; 9.36] 1.53[0.25; 9.36]Reindl-Schwaighofer, 202110%201NAnot evaluable venous thromboembolism detailed resultsReindl-Schwaighofer, 2021 2.03 [0.07; 61.21] 2.03[0.07; 61.21]Reindl-Schwaighofer, 202110%201NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-05-16 15:36 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 806,758,826,755 - roots T: 290